An Open-Label, Randomised, Two-Part Crossover Study to Assess the Pharmacokinetics of a Single Dose of SB-742457 Formulated as a Capsule and a Tablet in Healthy Elderly Volunteers.
Latest Information Update: 20 Aug 2023
Price :
$35 *
At a glance
- Drugs Intepirdine (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2007 New trial record.